The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes
Open accessAbstract
BACKGROUND: Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favorable effects on cardiorenal outcomes in patients with predominantly stage 3 or 4 chronic kidney disease (CKD) with severely elevated albuminuria and type 2 diabetes. The use of finerenone in patients with type 2 diabetes and a wider range of CKD is unclear. METHODS: (stage 1 or 2 CKD). Patients were treated with renin-angiotensin system blockade that had been adjusted before randomization to the maximum dose on the manufacturer's label that did not cause unacceptable side effects. The primary outcome, assessed in a time-to-event analysis, was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. The first secondary outcome was a composite of kidney failure, a sustained decrease from baseline of at least 40% in the eGFR, or death from renal causes. Safety was assessed as investigator-reported adverse events. RESULTS: A total of 7437 patients underwent randomization. Among the patients included in the analysis, during a median follow-up of 3.4 years, a primary outcome event occurred in 458 of 3686 patients (12.4%) in the finerenone group and in 519 of 3666 (14.2%) in the placebo group (hazard ratio, 0.87; 95% confidence interval [CI], 0.76 to 0.98; P = 0.03), with the benefit driven primarily by a lower incidence of hospitalization for heart failure (hazard ratio, 0.71; 95% CI, 0.56 to 0.90). The secondary composite outcome occurred in 350 patients (9.5%) in the finerenone group and in 395 (10.8%) in the placebo group (hazard ratio, 0.87; 95% CI, 0.76 to 1.01). The overall frequency of adverse events did not differ substantially between groups. The incidence of hyperkalemia-related discontinuation of the trial regimen was higher with finerenone (1.2%) than with placebo (0.4%). CONCLUSIONS: Among patients with type 2 diabetes and stage 2 to 4 CKD with moderately elevated albuminuria or stage 1 or 2 CKD with severely elevated albuminuria, finerenone therapy improved cardiovascular outcomes as compared with placebo. (Funded by Bayer; FIGARO-DKD ClinicalTrials.gov number, NCT02545049.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Of the secondary outcomes, the most noteworthy was a 36% reduction in kidney failure: 0.9% vs. 1.3% in the placebo group (HR 0.64 [95% CI 0.41-0.995]).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [144]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In patients with diabetic kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors,3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors,6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone8,9 all reduced the risk of progression to kidney failure.”
From Empagliflozin in Patients with Chronic Kidney Disease (2023) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There was a higher incidence of hyperkalemia in the finerenone group, 10.8% vs. 5.3%, although only 1.2% of the 3,686 individuals on finerenone stopped the study due to hyperkalemia.”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) outcome trial (460) demonstrates a significant relationship between reduction in moderately increased albuminuria and reduction in cardiovascular risk.”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [460]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Discontinuation of trial regimen was higher among those on fi nerenone than placebo (1.2% vs. 0.4%).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and no effect on HbA1c, no increase in hypo- or hyperglycemia, and no sexual side effects due to the speci fi city for the MRA.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients with T2D and albuminuria are known to be at high risk of CKD progression and cardiovascular events, and the FIDELIO-DKD and FIGARO-DKD trials demonstrated that fi nerenone reduced these events (particularly CKD progression and heart failure) among such patients.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The pooled analysis of two complementary trials comprising 13 026 patients with a broad spectrum of CKD and type 2 diabetes, all treated with an optimized dose of an ACEi or ARB,7 , 10 provides robust evidence of both cardiovascular and kidney protection with finerenone vs. placebo.”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There was a higher incidence of hyperkalemia in the finerenone group, 10.8% vs. 5.3%, although only 1.2% of the 3,686 individuals on finerenone stopped the study due to hyperkalemia.”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [144]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“People with type 2 diabetes and CKD should be considered for treatment with finerenone to reduce cardiovascular outcomes and the risk of CKD progression (239–242).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [240]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Finerenone was investigated in two complementary phase 3 studies of patients with T2D, kidney disease (defined primarily as ACR ≥30 mg/g), and potassium <4.8 mmol/L and is the only ns-MRA approved in the world for slowing CKD progression and reducing cardiovascular events.”
From Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) (2022) · cites this paper as [87]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The finerenone group showed a 13% reduction in the primary end point compared with the placebo group (12.4% vs. 14.2%;HR 0.87 [95% CI 0.76-0.98];P = 0.03).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [126]
The cited source says what the claim attributes to it.
In the citing paper
“Of the secondary outcomes, the most noteworthy was a 36% reduction in ESKD: 0.9% vs. 1.3% in the placebo group (HR 0.64 [95% CI 0.41-0.995]).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [126]
The cited source says what the claim attributes to it.
In the citing paper
“This benefit was primarily driven by a reduction in heart failure hospitalizations: 3.2% vs. 4.4% in the placebo group (HR 0.71 [95% CI 0.56-0.90]).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [126]
The cited source says what the claim attributes to it.
In the citing paper
“There was a 13% lower risk of the primary cardiovascular composite outcome, which included death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
The cited source says what the claim attributes to it.
In the citing paper
“The secondary composite kidney outcome, which included kidney failure, sustained decrease from baseline of at least 40% in eGFR, or death from kidney causes, was not signi fi cantly different between fi nerenone and placebo (HR 0.87, 95% CI 0.76 -1.01).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
The cited source says what the claim attributes to it.
In the citing paper
“On average, there was only a small reduction in systolic blood pressure (3 mm Hg) with fi nerenone compared to placebo, and no effect on HbA1c, no increase in hypo- or hyperglycemia, and no sexual side effects due to the speci fi city for the MRA.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
The cited source says what the claim attributes to it.
In the citing paper
“and fi nerenone reduced the risk of kidney and cardiovascular outcomes in 2 pivotal outcome trials.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
The cited source says what the claim attributes to it.
In the citing paper
“In FIGARO-DKD, finerenone significantly reduced the primary cardiovascular composite outcome risk in a broader patient population than studied in FIDELIO-DKD (patients with stage 2–4 CKD and moderately increased albuminuria, or stage 1–2 CKD with severely increased albuminuria).7 , 10”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“The FIDELIO-DKD trial was designed to detect a treatment effect of finerenone on kidney failure endpoints, whereas the FIGARO-DKD trial aimed to detect an effect on a cardiovascular composite primary endpoint.7 , 10”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“This benefit was primarily driven by a reduction in heart failure hospitalizations: 3.2% vs. 4.4% in the placebo group (HR 0.71 [95% CI 0.56-0.90]).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [144]
The cited source says what the claim attributes to it.
In the citing paper
“The finerenone group showed a 13% reduction in the primary end point compared with the placebo group (12.4% vs. 14.2%;HR 0.87 [95% CI 0.76-0.98];P = 0.03).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [144]
The cited source says what the claim attributes to it.
In the citing paper
“In the FIGARO-DKD trial, finerenone reduced the primary outcome of death from cardiovascular causes, nonfatal MI, nonfatal stroke, or hospitalization for heart failure (HR 0.87 [95% CI 0.76-0.98];P = 0.03) in people with type 2 diabetes and CKD (248).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [248]
The cited source says what the claim attributes to it.
In the citing paper
“Only 7.8% of all participants had a prior history of heart failure, and the incidence of hospitalization for heart failure was reduced in the finerenone-allocated treatment arm (HR 0.71 [95% CI 0.56-0.90]).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [248]
The cited source says what the claim attributes to it.
In the citing paper
“Only 7.8% of all participants had a prior history of heart failure, and the incidence of hospitalization for heart failure was reduced in the finerenone-allocated treatment arm (HR 0.71 [95% CI 0.56–0.90]).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [240]
The cited source says what the claim attributes to it.
In the citing paper
“In the FIGARO-DKD trial, finerenone reduced the primary outcome of death from cardiovascular causes, nonfatal MI, nonfatal stroke, or hospitalization for heart failure (HR 0.87 [95% CI 0.76–0.98]; P = 0.03) in people with type 2 diabetes and CKD (240).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [240]
The cited source says what the claim attributes to it.
In the citing paper
“In summary, FIDELIO-DKD and FIGARO-DKD demonstrated cardiovascular and kidney benefits for finerenone among people with T2D who were treated with standard of care (including an RAS inhibitor at maximally tolerated doses and good control of glycemia and BP) who were at high residual risk, based largely on albuminuria (ACR ≥30 mg/g).”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Physical activity and aerobic exercise guidelines are similar in persons with T2D independent of lean vs overweight/obese BMI.431,674,727,728”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [431]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Overall, the updated evidence review identifi ed 27 RCTs on MRA, with 5 RCTs comparing nonsteroidal MRA to placebo and/or standard of care.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [164]
Experimental — accuracy not yet measuredIn the citing paper
“According to two large randomized placebo-controlled trials targeted at T2DM and CKD patients, finerenone has been demonstrated to significantly reduce the occurrences of composite renal outcome”
In the citing paper
“and composite cardiovascular outcome (defined as a composite of nonfatal MI, nonfatal stroke, death from cardiovascular causes, or hospitalization for heart failure [HHF]), regardless of patients with or without established cardiovascular disease [16, 17].”
In the citing paper
“Even more recently, the non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone has been shown to confer both cardiovascular and kidney protection in patients with T2D and CKD, in both a dedicated kidney outcome trial and a dedicated cardiovascular outcome trial [22,23].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [23]
In the citing paper
“In FIGARO-DKD, finerenone significantly reduced the composite cardiovascular outcome, which was the primary outcome of the trial (HR: 0.87, 95% CI: 0.76-0.98).26”
In the citing paper
“FIDELIO-DKD and FIGARO-DKD each enrolled people with T2D treated with the maximum-tolerated dose of RASi who had residual albuminuria (ACR $30 mg/g [$3 mg/mmol]) and a nonelevated serum potassium (<4.8 mEq/l at screening).”
In the citing paper
“This recommendation is based on the high-quality evidence from FIDELIO-DKD and FIGARO-DKD (Grade A, summarized above) that finerenone slows progression of CKD and reduces risks of cardiovascular events in this population.25,26”
In the citing paper
“Two large clinical trials (Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease [FIDELIO-DKD] 25 and Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease [FIGARO-DKD] 26 ) and a pre-specified individual-level combined analysis of these 2 trials (The FInerenone in chronic kiDney diseasE and type 2 diabetes: Combined FIDELIO-DKD”
In the citing paper
“To mitigate hyperkalemia risk, the FIDELIO-DKD and FIGARO-DKD trials restricted eligibility to patients with non-elevated serum potassium concentration (after maximizing RASi) and implemented a standardized potassiummonitoring protocol.”
In the citing paper
“The HR of the primary outcome of cardiovascular death, nonfatal MI, nonfatal stroke, or hospitalization from heart failure was reduced by 13% in patients treated with fi nerenone.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [186]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationEffect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935
Self-citationChronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention
Gansevoort, R. T., Correa-Rotter, R., Hemmelgarn, B. R., Jafar, T. H., Heerspink, H. J. L., Mann, J. F., Matsushita, K., & Wen, C. P. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60595-4 · Cited by 2,213
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
Fox, C. S., Matsushita, K., Woodward, M., Bilo, H. J., Chalmers, J., Heerspink, H. J. L., Lee, B. J., Perkins, R. M., Rossing, P., Sairenchi, T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61350-6 · Cited by 1,401
Self-citationMcGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
Sotagliflozin in patients with diabetes and chronic kidney disease
Bhatt, D. L., Szarek, M., Pitt, B., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Inzucchi, S. E., Kosiborod, M. N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030186 · Cited by 1,205
Self-citationCoresh, J., Turin, T. C., Matsushita, K., Sang, Y., Ballew, S. H., Appel, L. J., Arima, H., Chadban, S. J., Cirillo, M., Djurdjev, O., et al. (2014) · JAMA · doi:10.1001/jama.2014.6634 · Cited by 988
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,000
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., Cherney, D. Z. I., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155931 · Cited by 99
Self-citationNew strategies to improve clinical outcomes for diabetic kidney disease
Forst, T. M., Mathieu, C., Giorgino, F., Wheeler, D. C., Παπάνας, Ν., Schmieder, R. E., Halabi, A., Schnell, O., Streckbein, M., & Tuttle, K. R. (2022) · BMC Medicine · doi:10.1186/s12916-022-02539-2 · Cited by 96
Bakris, G. L., Ruilope, L. M., Anker, S. D., Filippatos, G. S., Pitt, B., Rossing, P. R., Fried, L. P., Roy‐Chaudhury, P., Sarafidis, P. A., Ahlers, C., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.08.040 · Cited by 95
Self-citationPathomechanisms of Diabetic Kidney Disease
Sinha, S. K., & Nicholas, S. B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12237349 · Cited by 98
Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice
Lim, L.-L., Chow, E., & Chan, J. C. N. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00776-2 · Cited by 91
Hypertension and Type 2 Diabetes—The Novel Treatment Possibilities
Przezak, A., Bielka, W., & Pawlik, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126500 · Cited by 97
Screening, identifying, and treating chronic kidney disease: why, who, when, how, and what?
Farrell, D. R., & Vassalotti, J. A. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03466-5 · Cited by 95
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Kolkhof, P., Joseph, A., & Kintscher, U. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105859 · Cited by 91
Self-citationBiomarkers to Guide Medical Therapy in Primary Aldosteronism
Hundemer, G. L., Leung, A. A. C., Kline, G. A., Brown, J. M., Turcu, A. F., & Vaidya, A. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad024 · Cited by 92
Finerenone and Kidney Outcomes in Patients With Heart Failure
Mc Causland, F. R., Vaduganathan, M., Claggett, B. L., Kulac, I. J., Desai, A. S., Jhund, P. S., Henderson, A. D., Brinker, M., Perkins, R., Scheerer, M. F., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.10.091 · Cited by 86
Self-citationMoving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease
Tuttle, K. R., Wong, L., St. Peter, W., Roberts, G., Rangaswami, J., Mottl, A., Kliger, A. S., Harris, R. C., Gee, P. O., Fowler, K., et al. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02980322 · Cited by 87
Advances in the management of chronic kidney disease
Chen, T. K., Hoenig, M. P., Nitsch, D., & Grams, M. E. (2023) · BMJ · doi:10.1136/bmj-2022-074216 · Cited by 100
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 101
Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease
Pandey, A. K., Bhatt, D. L., Cosentino, F., Marx, N., Rotstein, O. D., Pitt, B., Pandey, A., Butler, J., & Verma, S. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac299 · Cited by 85
Self-citationMolecular Mechanisms of Diabetic Kidney Disease
Rico-Fontalvo, J. E., Aroca, G., Cabrales, J., Daza-Arnedo, R., Yánez, T. R., Martínez‐Ávila, M. C., Uparella-Gulfo, I., & Raad-Sarabia, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158668 · Cited by 84
The Cardio-Kidney Patient: Epidemiology, Clinical Characteristics and Therapy
Schuett, K. A., Marx, N., & Lehrke, M. (2023) · Circulation Research · doi:10.1161/circresaha.122.321748 · Cited by 89
Judge, P. K., Tuttle, K. R., Staplin, N., Hauske, S. J., Zhu, D., Sardell, R. J., Cronin, L., Green, J. B., Agrawal, N., Arimoto, R., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae263 · Cited by 84
Self-citationProvenzano, M., Jongs, N., Vart, P., Stefánsson, B. V., Chertow, G. M., Langkilde, A. M., McMurray, J. J. V., Correa‐Rotter, R., Rossing, P. R., Sjöström, C. D., et al. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.12.013 · Cited by 84
Self-citationCardiovascular Disease in Diabetes and Chronic Kidney Disease
Swamy, S., Noor, S. M., & Mathew, R. O. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12226984 · Cited by 88
Kidney outcomes with finerenone: an analysis from the FIGARO-DKD study
Ruilope, L. M., Pitt, B., Anker, S. D., Rossing, P. R., Kovesdy, C. P., Pecoits‐Filho, R., Pérgola, P. E., Joseph, A., Lage, A. Z., Mentenich, N., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac157 · Cited by 82
Self-citationYeo, S. C., Wang, H., Ang, G. Y., Lim, C. K., & Ooi, X. Y. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad137 · Cited by 84
Filippatos, G. S., Anker, S. D., Pitt, B., Rossing, P. R., Joseph, A., Kolkhof, P., Lambelet, M., Lawatscheck, R., Bakris, G. L., Ruilope, L. M., et al. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.07.013 · Cited by 81
Self-citationHow to Manage Heart Failure With Preserved Ejection Fraction
Desai, A. S., Lam, C. S. P., McMurray, J. J. V., & Redfield, M. M. (2023) · JACC Heart Failure · doi:10.1016/j.jchf.2023.03.011 · Cited by 83
Predicting and preventing heart failure in type 2 diabetes
Pandey, A., Khan, M. S., Patel, K. V., Bhatt, D. L., & Verma, S. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00128-6 · Cited by 84
Diabetes and its complications: molecular mechanisms, prevention and treatment
Zhao, L., Yuan, J., Yang, Q., Ma, J., Yang, F., Zou, Y., Liu, K., & Liu, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02401-w · Cited by 80
Hypertension and Heart Failure: From Pathophysiology to Treatment
Gallo, G., & Savoia, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126661 · Cited by 88
2026 ESC Guidelines for the management of heart failure
Køber, L., Adamo, M., Ruwald, A., Tomasoni, D., Anderson, L., Andersson, C., Brugts, J. J., Chioncel, O. D., Donal, E., Ferdinandy, P., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag100 · Cited by 109
Tsai, M., Kao, J. T., Wong, C., Liao, C.-T., Lo, W., Chien, K., Wen, C.-P., Wu, K., & Wu, M. (2025) · PLoS Medicine · doi:10.1371/journal.pmed.1004629 · Cited by 81
Cardiorenal benefits of finerenone: protecting kidney and heart
González‐Juanatey, J. R., Górriz, J. L., Ortíz, A., Valle, A., Soler, M. J., & Fácila, L. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2171110 · Cited by 83
An IL-6/STAT3/MR/FGF21 axis mediates heart-liver cross-talk after myocardial infarction
Sun, J.-Y., Du, L., Shi, X., Zhang, Y., Liu, Y., Wang, Y.-L., Chen, B., Liu, T., Zhu, H., Liu, Y., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade4110 · Cited by 77
Nicholas, S. B., Daratha, K. B., Alicic, R. Z., Jones, C. R., Kornowske, L. M., Neumiller, J. J., Fatoba, S., Kong, S. X., Singh, R., Norris, K. C., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15194 · Cited by 77
Khan, S. S., Breathett, K., Braun, L. T., Chow, S. L., Gupta, D. K., Lekavich, C., Lloyd-Jones, D. M., Ndumele, C. E., Rodriguez, C. J., Allen, L. A., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001307 · Cited by 75
Role of the Microbiome in Gut-Heart-Kidney Cross Talk
Glorieux, G., Nigám, S. K., Vanholder, R. C., & Verbeke, F. (2023) · Circulation Research · doi:10.1161/circresaha.123.321763 · Cited by 80
Solomon, S. D., Ostrominski, J. W., Vaduganathan, M., Claggett, B. L., Jhund, P. S., Desai, A. S., Lam, C. S. P., Pitt, B., Senni, M., Shah, S. J., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3266 · Cited by 76
Self-citationLv, R., Xu, L., Che, L., Liu, S., Wang, Y., & Dong, B. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1125693 · Cited by 74
Mark, P. B., Sarafidis, P. A., Ekart, R., Ferro, C. J., Balafa, O. C., Fernández‐Fernández, B., Herrington, W. G., Rossignol, P., Vecchio, L. D., Valdivielso, J. M., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad112 · Cited by 76
Bae, J. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0220 · Cited by 87
Kidney Fibrosis and Oxidative Stress: From Molecular Pathways to New Pharmacological Opportunities
Patera, F., Gatticchi, L., Cellini, B., Chiasserini, D., & Reboldi, G. (2024) · Biomolecules · doi:10.3390/biom14010137 · Cited by 74
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae212 · Cited by 73
Ortíz, A., Guerra, J. M. A., Chan, J. C. N., Jha, V., Kramer, H., Nicholas, S. B., Pavkov, M. E., Wanner, C., Wong, L. P., Cheung, M., et al. (2025) · Kidney International · doi:10.1016/j.kint.2025.04.005 · Cited by 82
Self-citationKanugula, A. K., Kaur, J., Batra, J., Ankireddypalli, A. R., & Velagapudi, R. (2023) · Cureus · doi:10.7759/cureus.40725 · Cited by 73
Aldosterone and cardiovascular diseases
Parksook, W. W., & Williams, G. H. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac027 · Cited by 69
Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
Kim, D., Lee, S., & Kim, N. H. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1629 · Cited by 69
Prevention of cardiorenal complications in people with type 2 diabetes and obesity
Drucker, D. J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.12.018 · Cited by 68
Aldosterone and aldosterone synthase inhibitors in cardiorenal disease
Verma, S., Pandey, A., Pandey, A. K., Butler, J., Lee, J. S., Teoh, H., Mazer, C. D., Kosiborod, M., Cosentino, F., Anker, S. D., et al. (2023) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00419.2023 · Cited by 69
Self-citationHobbs, R. F., McManus, R. J., Taylor, C. J., Jones, N. R., Rahman, J. K., Wolstenholme, J. L., Kim, S., Kwon, J., Jones, L., Hirst, J. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03263-5 · Cited by 70
Brown, J. M., Wijkman, M. O., Claggett, B. L., Shah, A. M., Ballantyne, C. M., Coresh, J., Grams, M. E., Wang, Z., Yu, B., Boerwinkle, E., et al. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.19134 · Cited by 66
Heart Failure: An Update from the Last Years and a Look at the Near Future
Riccardi, M., Sammartino, A. M., Piepoli, M. F., Adamo, M., Pagnesi, M., Rosano, G. M. C., Metra, M., von Haehling, S., & Tomasoni, D. (2022) · ESC Heart Failure · doi:10.1002/ehf2.14257 · Cited by 66
Mahaffey, K. W., Tuttle, K. R., Arici, M., Baeres, F. M. M., Bakris, G. L., Charytan, D. M., Cherney, D. Z. I., Chernin, G., Correa‐Rotter, R., Gumprecht, J., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae613 · Cited by 66
Self-citationGuideline for the Management of Diabetes Mellitus in the Elderly in China (2024 Edition)
Guo, L., & Xiao, X. (2024) · Aging Medicine · doi:10.1002/agm2.12294 · Cited by 69
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108101 · Cited by 64
Self-citationHyperkalemia in Chronic Kidney Disease: Links, Risks and Management
Sarnowski, A., Gama, R. M., Dawson, A., Mason, H., & Banerjee, D. (2022) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s326464 · Cited by 71
Kolkhof, P., Lawatscheck, R., Filippatos, G. S., & Bakris, G. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169243 · Cited by 64
Self-citationCKD-Associated Cardiovascular Mortality in the United States: Temporal Trends From 1999 to 2020
Kobo, O. M., Abramov, D., Davies, S., Ahmed, S. B., Sun, L. Y., Mieres, J. H., Parwani, P. J., Siudak, Z., Spall, H. G. C. V., & Mamas, M. A. (2022) · Kidney Medicine · doi:10.1016/j.xkme.2022.100597 · Cited by 64
Savarese, G., Lindberg, F., Filippatos, G. S., Butler, J., & Anker, S. D. (2023) · Diabetologia · doi:10.1007/s00125-023-06031-1 · Cited by 64
Self-citationHeerspink, H. J. L., Birkenfeld, A. L., Cherney, D. Z. I., Colhoun, H. M., Ji, L., Mathieu, C., Groop, P.-H., Pratley, R. E., Rosas, S. E., Rossing, P., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110908 · Cited by 63
Self-citationKidney fibrosis: Emerging diagnostic and therapeutic strategies
Klinkhammer, B. M., & Boor, P. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101206 · Cited by 65
Contemporary review of IgA nephropathy
Filippone, E. J., Gulati, R., & Farber, J. L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1436923 · Cited by 66
Delanaye, P., & Scheen, A. J. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101285 · Cited by 64
Ortíz, A., Wanner, C., Gansevoort, R. T., Ortíz, A., Wanner, C., Gansevoort, R. T., Cozzolino, M. G., Fliser, D., Gambaro, G., Ong, A. C. M., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac257 · Cited by 62
Georgianos, P. I., & Agarwal, R. (2022) · American Journal of Hypertension · doi:10.1093/ajh/hpac124 · Cited by 63
Self-citationOutcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes
Sarafidis, P. A., Agarwal, R., Pitt, B., Wanner, C., Filippatos, G. S., Boletis, J., Tuttle, K. R., Ruilope, L. M., Rossing, P. R., Toto, R., et al. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000149 · Cited by 61
Self-citationA kidney-brain neural circuit drives progressive kidney damage and heart failure
Cao, W., Yang, Z., Liu, X., Ren, S., Su, H., Yang, B., Liu, Y., Wilcox, C. S., & Hou, F. F. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01402-x · Cited by 61
Diagnosis and management of resistant hypertension
Schiffrin, E. L., & Fisher, N. D. L. (2024) · BMJ · doi:10.1136/bmj-2023-079108 · Cited by 64
Hofherr, A., Williams, J. H., Gan, L., Söderberg, M. P., Hansen, P., & Woollard, K. J. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02794-8 · Cited by 61
A Review on Diabetic Retinopathy
Kour, V., Swain, J., Singh, J., Singh, H., & Kour, H. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998253672231011161400 · Cited by 61
Update on the Pathogenesis, Diagnosis, and Treatment of Diabetic Tubulopathy
Liu, D., Chen, X., He, W., Lu, M., Li, Q., Zhang, S., Xie, J., Zhang, Y., & Wang, W. (2024) · Integrative Medicine in Nephrology and Andrology · doi:10.1097/imna-d-23-00029 · Cited by 60
Structural and molecular determinants of mineralocorticoid receptor signalling
Großmann, C., Almeida‐Prieto, B., Nolze, A., & de la Rosa, D. Á. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15746 · Cited by 64
Yang, Q., Lang, Y., Yang, W., Yang, F., Yang, J., Wu, Y., Xiao, X., Qin, C., Zou, Y., Zhao, Y., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110592 · Cited by 62
Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials
Oraii, A., Healey, J. S., Kowalik, K., Pandey, A. K., Benz, A. P., Wong, J. A., Conen, D., & McIntyre, W. F. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehad811 · Cited by 57
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection
Mazzieri, A., Porcellati, F., Timio, F., & Reboldi, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073969 · Cited by 58
Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024
ZHANG, S.-Y. (2025) · 老年心脏病学杂志：英文版 · doi:10.26599/1671-5411.2025.03.002 · Cited by 60
Proteomic cardiovascular risk assessment in chronic kidney disease
Deo, R., Dubin, R. F., Ren, Y., Murthy, A. C., Wang, J., Zheng, H., Zheng, Z., Feldman, H. I., Shou, H., Coresh, J., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad115 · Cited by 57
Kintscher, U., & Edelmann, F. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01899-0 · Cited by 58
Mårup, F. H., Thomsen, M. B., & Birn, H. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad249 · Cited by 56
Primordial Drivers of Diabetes Heart Disease: Comprehensive Insights into Insulin Resistance
Fan, Y., Yan, Z., Li, T., Li, A., Fan, X., Qi, Z., & Zhang, J. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0110 · Cited by 56
Awdishu, L., Maxson, R., Gratt, C., Rubenzik, T. T., & Battistella, M. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf044 · Cited by 56
Barrera‐Chimal, J., Kolkhof, P., Lima‐Posada, I., Alexandre, J., Rossignol, P., & Jaisser, F. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.2002844 · Cited by 54
Self-citationNovel Therapies for Alport Syndrome
Chavez, E., Rodriguez, J., Drexler, Y. R., & Fornoni, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.848389 · Cited by 59
Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks
Mullen, N., Curneen, J. M. G., Donlon, P. T., Prakash, P., Bancos, I., Gurnell, M., & Dennedy, M. C. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad026 · Cited by 55
Heart Failure in Patients with Chronic Kidney Disease
Xanthopoulos, A. V., Papamichail, A., Briasoulis, Α., Loritis, K., Bourazana, A., Magouliotis, D. E., Sarafidis, P. A., Stefanidis, I., Skoularigis, J. S., & Triposkiadis, F. K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12186105 · Cited by 56
Xu, C., Ha, X., Yang, S., Tian, X., & Jiang, H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1232790 · Cited by 60
Insulin Resistance and Insulin Handling in Chronic Kidney Disease
Parvathareddy, V. P., Wu, J., & Thomas, S. S. (2023) · Comprehensive physiology · doi:10.1002/cphy.c220019 · Cited by 54
Shubrook, J. H., Neumiller, J. J., & Wright, E. E. (2021) · Postgraduate Medicine · doi:10.1080/00325481.2021.2009726 · Cited by 54
Ortíz, A., Wanner, C., Gansevoort, R. T., Ortíz, A., Wanner, C., Gansevoort, R. T., Cozzolino, M. G., Fliser, D., Gambaro, G., Ong, A. C. M., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac186 · Cited by 52
Guedes, M. H., & Pecoits‐Filho, R. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13424 · Cited by 53
Tang, J., Liu, F., Cooper, M. E., & Chai, Z. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2133698 · Cited by 50
Renin–Angiotensin–Aldosterone System: From History to Practice of a Secular Topic
Ksiazek, S. H., Hu, L., Andò, S., Pirklbauer, M., Säemann, M. D., Ruotolo, C., Zaza, G., Manna, G. L., Nicola, L. D., Mayer, G. J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25074035 · Cited by 57
Kobayashi, M., Pitt, B., Ferreira, J. P., Rossignol, P., Girerd, N., & Zannad, F. M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf225 · Cited by 51
Self-citationAldosterone and Aldosterone Modulation in Cardio-Kidney Diseases
Fioretti, F., Testani, J. M., Tio, M. C., Pitt, B., & Butler, J. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.06.012 · Cited by 51
Self-citationLullo, L. D., Lavalle, C., Scatena, A., Mariani, M. V., Ronco, C., & Bellasi, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12123992 · Cited by 49
Sawami, K., Tanaka, A., & Node, K. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02500-y · Cited by 50
JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure
Kitai, T., Kohsaka, S., Kato, T., Kato, E. T., Sato, K., TERAMOTO, K., Yaku, H., Akiyama, E., Ando, M., Izumi, C., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.014 · Cited by 58
Xu, Y., Fu, E. L., Clase, C. M., Mazhar, F., Jardine, M., & Carrero, J. J. (2021) · Kidney International · doi:10.1016/j.kint.2021.10.033 · Cited by 50
Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation
Azizi, M., Mahfoud, F., Weber, M. A., Sharp, A. S. P., Schmieder, R. E., Lurz, P. C., Lobo, M. D., Fisher, N. D. L., Daemen, J., Bloch, M. J., et al. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.3904 · Cited by 49
Sarafidis, P. A., Iatridi, F., Ferro, C. J., Alexandrou, M. E., Fernández‐Fernández, B., Kanbay, M., Mallamaci, F., Nistor, I., Rossignol, P., Wanner, C., et al. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfad139 · Cited by 47
JCS 2023 Guideline on the Primary Prevention of Coronary Artery Disease
Fujiyoshi, A., Kohsaka, S., Hata, J., Hara, M., Kai, H., Masuda, D., Miyamatsu, N., Nishio, Y., Ogura, M., Sata, M., et al. (2024) · Circulation Journal · doi:10.1253/circj.cj-23-0285 · Cited by 55
Zhang, H., Wang, K., Zhao, H., Qin, B., Cai, X., Wu, M., Li, J., & Wang, J. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1631053 · Cited by 51
Bauersachs, J. K., & Lother, A. (2022) · Kidney International Supplements · doi:10.1016/j.kisu.2021.11.001 · Cited by 46
Metadata
- Authors
- Pitt, B., Filippatos, G., Agarwal, R., Anker, S. D., Bakris, G. L., Rossing, P., Joseph, A., Kolkhof, P., Nowack, C., Schloemer, P., & Ruilope, L. M.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-12-09
- Volume
- 385
- Issue
- 24
- Pages
- 2252-2263
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3194763937
- Cited by
- 1,814
- References
- 32
- Citations by year
- 2026: 439 · 2025: 435 · 2024: 331 · 2023: 315 · 2022: 250 · 2021: 41
- FWCI
- 160.23
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- National University of Singapore (submittedVersion)
- ABACUS. Repositorio de Producción Científica (Universidad Europea) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Bayer (ClinicalTrials.gov NCT02545049)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- mineralocorticoid receptor antagonists, type 2 diabetes, chronic kidney disease, cardiovascular events, heart failure hospitalization, albuminuria, renin-angiotensin system blockade, hyperkalemia, estimated glomerular filtration rate decline, renal failure, cardiorenal outcomes, FIDELIO-DKD
- MeSH terms
- Aged, Albuminuria, Mineralocorticoid Receptor Antagonists, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Hospitalization, Humans, Male, Middle Aged, Naphthyridines, Proportional Hazards Models, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
